BioCentury
ARTICLE | Clinical News

Lymphoseek tilmanocept: Phase II started

February 22, 2016 8:00 AM UTC

Navidea began the open-label, U.S. Phase II NAV3-19 trial to evaluate a single peritumoral dose of 50 ug Lymphoseek before surgery in up to 40 patients with cervical cancer who are undergoing lymph no...